Zogenix Inc.‘s launch of the long-acting hydrocodone formulation Zohydro will test the theory that there is no such thing as bad publicity.
The commercial availability of the new opioid pain therapy was hailed by headlines in national media outlets around the country in the first week of March. Unfortunately for Zogenix, those...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?